An analyst at a hot health policy think tank in Washington is defending pharmacy benefit managers' rebate strategy.
PBMs often negotiate deals for insurers and self-insured employer plans that offer the plan a rebate, or discount, off a covered drug's list price when enrollees use the drug.
Drugmakers and many pharmacy owners want Congress to ban the PBM rebate strategy, arguing that it gives the PBMs incentive to drive the list prices of drugs up to absurd levels, and that PBMs and health insurers keep most of the rebate money.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
